Head-to-head · computed 2026-08-11
bmiMD vs TMates
bmiMD: bmiMD is a compounded GLP-1 telehealth platform notable for flat per-dose pricing — the rate stays the same whether you're at 2.5 mg or 15 mg — and one of the widest plan-tier menus in the market. Its $99/mo semaglutide and $139/mo tirzepatide on the twelve-month plan are the lowest annualized figures in the dataset for both molecules. TMates: TMates is a compounded GLP-1 telehealth service that includes medication and visits in one bundled monthly price. It offers both semaglutide and tirzepatide, with a 12-month plan that brings tirzepatide to $167/mo — the lowest committed-plan figure for tirz outside of bmiMD and NexLife.
Tirzepatide
| bmiMD | TMates | |
|---|---|---|
| All-in maintenance | $179/mo | $297/mo |
| Best plan rate | $139/mo | $167/mo |
| 12-month total | $1,668 | $2,004 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-14 |
The arithmetic
On the figures our desk holds, bmiMD's $179 a month undercuts TMates's $297 by $118 a month at the 10 mg/wk maintenance basis — $1,416 across a year. bmiMD's figure is reported (captured 2026-07-14) and TMates's is reported (captured 2026-07-14); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's tirzepatide ladder runs $179 a month billed monthly, $159 a month on a three-month plan, $149 a month on a six-month plan, and $139 a month on a twelve-month plan. TMates's runs $297 a month billed monthly, and $167 a month on a twelve-month plan. On the twelve-month basis bmiMD's $1,668 beats TMates's $2,004 by $336 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Semaglutide
| bmiMD | TMates | |
|---|---|---|
| All-in maintenance | $129/mo | $249/mo |
| Best plan rate | $99/mo | $158/mo |
| 12-month total | $1,188 | $1,896 |
| Status | Reported · 2026-07-14 | Reported · 2026-07-14 |
The arithmetic
On the figures our desk holds, bmiMD's $129 a month undercuts TMates's $249 by $120 a month at the 2.4 mg/wk maintenance basis — $1,440 across a year. bmiMD's figure is reported (captured 2026-07-14) and TMates's is reported (captured 2026-07-14); a status below 'verified' means our independent checkout capture is still pending, so treat the gap as the best current evidence rather than settled fact.
bmiMD's semaglutide ladder runs $129 a month billed monthly, $119 a month on a three-month plan, $109 a month on a six-month plan, and $99 a month on a twelve-month plan. TMates's runs $249 a month billed monthly, and $158 a month on a twelve-month plan. On the twelve-month basis bmiMD's $1,188 beats TMates's $1,896 by $708 — with the winner's figure resting on a committed twelve-month plan, a structural difference that matters if you might stop early.
Where the structures genuinely differ
On dose economics, bmiMD is dose-flat — the price survives titration — while TMates's pricing can move with the dose, a difference that compounds through a standard escalation schedule and matters most to buyers expecting to reach the higher maintenance doses.
Structure, side by side
bmiMD
- MembershipNone
- Dose policyFlat — same price at every dose, across all plan lengths
- CommitmentMonthly, 3-month, 6-month, or 12-month plans; price varies by term, not by dose
- CancellationPer provider terms; confirm cancellation policy at enrollment
- PharmacyNamed 503A pharmacy partner (specific pharmacy not publicly identified on pricin
TMates
- MembershipNone
- Dose policyStructured titration; medication and provider visits included in price
- Commitment12-month plan or month-to-month; substantial difference in rates
- CancellationPer provider terms
- PharmacyPartner 503A pharmacy (not publicly named)
What our desk is watching on each
bmiMD: bmiMD's 12-month semaglutide plan at $99/mo is the lowest annualized sema figure in our dataset, beating NexLife's $119/mo and Oak's $133 m2m. Month-to-month sema at $129 also beats Oak's $133, making bmiMD the new m2m sema leader. Tirzepatide 12-month at $139 ties NexLife. Figures are reported status from RangeYourself's July 2026 first-party captures; our independent checkout is pending.
TMates: The $158/mo (sema) and $167/mo (tirz) headline figures are 12-month plan rates; month-to-month is $249 (sema) and $297 (tirz) — some of the widest start-to-commitment spreads in the index. Reported status from RangeYourself 2026-07-14 verification.
Questions people ask
Is bmiMD or TMates cheaper in 2026?
The tirzepatide and semaglutide verdict blocks above give the computed answer at the maintenance basis, with the verification status of each figure; the short version is that whichever program's all-in monthly number is lower on this page is cheaper on the evidence we hold today, and both rows carry capture dates so you can judge freshness.
What does bmiMD vs TMates miss that checkout will show?
Taxes, state availability, current promotions, and any dose surcharge introduced after our capture date. Screenshot the order summary before paying — that capture, not any comparison page, is your contract.
Why do you compare at the maintenance dose instead of the starting dose?
Because starter pricing lasts one or two months and maintenance pricing lasts the rest of the year; comparing starts against maintenances is the single most common way GLP-1 comparisons mislead.
What do bmiMD and TMates cost over a full year of tirzepatide?
On the plans our database holds, a year of tirzepatide runs $1,668 at bmiMD and $2,004 at TMates — computed from each program's best published twelve-month route, with promotional figures labeled in the sections above and every number carrying its capture date.
Both records live in the normalized database; re-run the math yourself from the downloads. Full record pages: bmiMD · TMates. Official sites: bmiMD ↗ · TMates ↗. Nothing here is medical advice.